Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4417-4426.
Prepublished online as a Blood First Edition Paper on August 30, 2007; DOI 10.1182/blood-2007-05-092098.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-05-092098v1
110/13/4417    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leleu, X.
Right arrow Articles by Ghobrial, I. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leleu, X.
Right arrow Articles by Ghobrial, I. M
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted May 25, 2007
Accepted August 20, 2007

The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia

Xavier Leleu, Xiaoying Jia, Judith Runnels, Hai T Ngo, Anne-Sophie Moreau, Mena Farag, Joel A Spencer, Costas M Pitsillides, Evdoxia Hatjiharissi, Aldo Roccaro, Garrett O'Sullivan, Douglas W. McMillin, Daisy Moreno, Tanyel Kiziltepe, Ruben Carrasco, Steven P Treon, Teru Hideshima, Kenneth C Anderson, Charles P Lin, and Irene M Ghobrial*

Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
Advanced Microscopy Program, Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, United States
Service des maladies du sang et Laboratoire d'Immunologie, CHRU, Lille, France

* Corresponding author; email: irene_ghobrial{at}dfci.harvard.edu.

Waldenstrom Macroglobulinemia (WM) is an incurable low-grade lymphoplasmacytic lymphoma. We demonstrate upregulated Akt activity in WM, and that Akt downregulation by Akt knockdown and the inhibitor perifosine leads to significant inhibition of proliferation and induction of apoptosis in WM cells in vitro, but not in normal donor peripheral blood and hematopoietic progenitors. Importantly, downregulation of Akt induced cytotoxicity of WM cells in the bone marrow microenvironment (BMM) context. Perifosine induced significant reduction in WM tumor growth in vivo in a subcutaneous xenograft model through inhibition of Akt phosphorylation and downstream targets. We also demonstrated that Akt pathway downregulation inhibited migration and adhesion in vitro and homing of WM tumor cells to the BMM in vivo. Proteomic analysis identified other signaling pathways modulated by perifosine, such as activation of ERK MAPK pathway, that induces survival of tumor cells. Interestingly, MEK inhibitor significantly enhanced perifosine-induced cytotoxicity in WM cells. Using Akt knockdown experiments and specific Akt and PI3K inhibitors, we demonstrated that ERK activation is through a direct effect, rather than feedback activation, of perifosine upstream ERK pathway. These results provide understanding of biological effects of Akt pathway in WM, and provide the framework for clinical evaluation of perifosine in WM patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
S. Poulain, I. Dervite, X. Leleu, V. Coiteux, P. Duthilleul, and P. Morel
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less
Haematologica, July 1, 2008; 93(7): 1109 - 1111.
[Full Text] [PDF]


Home page
BloodHome page
H. T. Ngo, X. Leleu, J. Lee, X. Jia, M. Melhem, J. Runnels, A.-S. Moreau, N. Burwick, A. K. Azab, A. Roccaro, et al.
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia
Blood, July 1, 2008; 112(1): 150 - 158.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al.
Targeting NF-{kappa}B in Waldenstrom macroglobulinemia
Blood, May 15, 2008; 111(10): 5068 - 5077.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. M. Roccaro, X. Leleu, A. Sacco, X. Jia, M. Melhem, A.-S. Moreau, H. T. Ngo, J. Runnels, A. Azab, F. Azab, et al.
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
Blood, May 1, 2008; 111(9): 4752 - 4763.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Roccaro, X. Leleu, A. Sacco, A.-S. Moreau, E. Hatjiharissi, X. Jia, L. Xu, B. Ciccarelli, C. J. Patterson, H. T. Ngo, et al.
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstrom's Macroglobulinemia
Clin. Cancer Res., March 15, 2008; 14(6): 1849 - 1858.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020